Low sales, high cost: Melin­ta slash­es HQ re­search staff as it strug­gles to grow an­tibi­otics rev­enue

7 years ago
R&D

The num­ber of I/O can­cer drugs in the clin­ic con­tin­ues to swell at an ex­plo­sive pace -- of­fer­ing new hope, fresh ...

7 years ago
R&D

Af­ter get­ting beat up on its de­pres­sion drug pitch, a bat­tered Alk­er­mes piv­ots to schiz­o­phre­nia with a pos­i­tive PhI­II ...

7 years ago
R&D

Cat­a­lyst Phar­ma's LEMS drug Fir­dapse wins FDA nod, as reg­u­la­tors keep the ap­proval en­gine run­ning at record speed

7 years ago
Pharma

Af­ter a long, hard slog to the clin­ic, stem cell play­er Vi­a­Cyte fu­els up with $105M for its next big at­tack on ...

7 years ago
Financing

FDA stamps fast OK on Astel­las' pi­o­neer­ing FLT3 AML drug gilter­i­tinib, ex­pand­ing on a record year for new ap­provals

7 years ago
Pharma

Can a $1B IPO at­tract leery in­vestors on HKEX? WuXi AppTec is set to find out

7 years ago
Financing
China

No­var­tis HQ is pulling up its roots in the UK and mov­ing to a new biotech cam­pus in Lon­don

7 years ago
Pharma

In­cyte hires Janssen ex­ec as CSO Hu­ber moves to Third Rock; Syn­thorx set terms for $100M IPO

7 years ago
News Briefing

The flip side of the hot IPO mar­ket? A chill could trig­ger a sud­den cash crunch in biotech, fol­lowed by more deals

7 years ago
Financing

Found­ed by for­mer Phar­mas­set, Idenix ex­ecs, hep B com­pa­ny An­tios nabs $25M Se­ries A

7 years ago
Financing

Can a biotech uni­corn break in­to the record books with a $600M IPO? Stéphane Ban­cel has a for­tune rid­ing on the ...

7 years ago
Financing

Bio­Haven hopes to soothe Chi­nese headaches with Shang­hai sub­sidiary

7 years ago
China

At the cen­ter of a glob­al tem­pest, Jiankui He de­fends edit­ing the genes of 2 new­borns

7 years ago
China

FDA warns in­ves­ti­ga­tor for vi­o­lat­ing clin­i­cal hold

7 years ago
Pharma

Gi­ant Roche wades in­to the pre­clin­i­cal NL­RP3 pool, bag­ging Je­cure for their an­ti-in­flam­ma­to­ry team at Genen­tech

7 years ago
Deals

BeiGene inks $60M li­cens­ing, re­search pacts with Zymeworks; Mer­ck, Ab­b­Vie, Am­gen back neu­ro up­start

7 years ago
News Briefing

On a roll, Ver­tex racks up im­pres­sive PhI­II da­ta for VX-659 com­bos in cys­tic fi­bro­sis

7 years ago
R&D

In the lat­est re­verse merg­er, Vi­en­na's Ar­sa­nis serves as ve­hi­cle for X4 Phar­ma's Nas­daq list­ing

7 years ago
Pharma

New­ly named Abeona chief Carsten Thiel boot­ed af­ter the board ac­cus­es him of mis­con­duct in­volv­ing col­leagues

7 years ago
People

Welling­ton, HBM lead €24M round as Adrenomed preps sep­tic shock treat­ment for hu­man test­ing

7 years ago
Financing

Glob­al syn­di­cate backs $400M ge­nomics R&D play in Ire­land as WuXi NextCODE ex­tends its reach in­to Eu­rope

7 years ago
Financing
R&D

Trump pro­pos­al ta­pers Medicare pro­tec­tion for cer­tain drugs if drug­mak­ers don't tem­per pric­ing

7 years ago
Pharma

Shat­ter­ing an old record, FDA quick­ly OKs pi­o­neer­ing, site-ag­nos­tic can­cer drug larotrec­tinib from Loxo and Bay­er

7 years ago
Pharma
First page Previous page 978979980981982983984 Next page Last page
A service from the Financial Times